ArticleThe American journal of pathology2010
Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.
Article in The American journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 103 citations in OpenAlex.
- A randomized clinical trial of omega-3 fatty acid and vitamin D supplementation on electrocardiographic risk profiles.Scientific reports · 2023Trial
- Trial
- Trial
- The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study.BMC nephrology · 2014Trial
- Cardiovascular effects of cholecalciferol treatment in dialysis patients--a randomized controlled trial.BMC nephrology · 2014Trial
- Sirtuin 1 mediates the pro-survival effects of vitamin D in angiotensin II-induced hypertrophy of H9c2 cardiomyoblasts.Molecular biology reports · 2024Article
- Inhibition of GTPase Rac1 expression by vitamin D mitigates pressure overload-induced cardiac hypertrophy.International journal of cardiology. Heart & vasculature · 2021Article
- Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease.Journal of cardiovascular development and disease · 2021Article
- The Protective Effect of 1,25(OH)Frontiers in cell and developmental biology · 2021Article
- Vitamin D deficiency among patients with pulmonary hypertension.BMC pulmonary medicine · 2019Article
- Article
- ATP-citrate lyase is an epigenetic regulator to promote obesity-related kidney injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Does alfacalcidol reduce cardiovascular complications in hemodialysis patients?Annals of translational medicine · 2019Article
- Serum Vitamin D Level in Patients with Coronary Artery Disease and Association with Sun Exposure: Experience from a Tertiary Care, Teaching Hospital in India.Advances in medicine · 2019Article
- Vitamin D Regulates the Expressions of AQP-1 and AQP-4 in Mice Kidneys.BioMed research international · 2019Article
- Role of Vitamin D Beyond the Skeletal Function: A Review of the Molecular and Clinical Studies.International journal of molecular sciences · 2018Review
- Vitamin D and Calcimimetics in Cardiovascular Disease.Seminars in nephrology · 2018Review
- The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.Endocrinology and metabolism clinics of North America · 2017Review
- Involvement of the Vitamin D Receptor in Energy Metabolism Revealed by Profiling of Lysine Succinylome of White Adipose Tissue.Scientific reports · 2017Article
- Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients.Pediatric nephrology (Berlin, Germany) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Vitamin D inhibits renin expression and blocks the compensatory induction of renin associated with the use of renin-angiotensin system inhibitors. Here we test the therapeutic effects of two commonly used vitamin D analogs and their combination with losartan on the development of left ventricular hypertrophy. One-month-old male spontaneously hypertensive rats were treated with vehicle, losartan, paricalcitol, doxercalciferol, a combination of losartan and paricalcitol, or a combination of losartan and doxercalciferol for 2 months. Blood pressure was markedly reduced by losartan, but not by paricalcitol or doxercalciferol alone. Echocardiograpy demonstrated a 65 to 80% reduction in left ventricular wall thickness with losartan, paricalcitol, or doxercalciferol monotherapy and almost complete prevention of left ventricular hypertrophy with the combination therapies. Attenuation of cardiac and cardiomyocyte hypertrophy, and suppression of atrial and brain natriuretic peptides, were most marked in the combination therapy groups. These changes were well correlated with left ventricular gene and microRNA expression profiles in the different treatment groups. Renal and cardiac renin expression was markedly increased in losartan-treated animals, but nearly normalized with combination therapy. The same vitamin D analogs suppressed plasma renin activity in patients receiving chronic hemodialysis. These data demonstrate that vitamin D analogs have potent antihypertrophic activity in part via suppression of renin in the kidney and heart, and combination of these analogs with losartan achieves much better therapeutic effects because of the blockade of the compensatory renin increase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.